The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams

Neuroscience of Dreaming, Healthy Clinical Trial

Official title:

The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02792140
• Other study ID #: 2015DR2186
• Status: Completed
• Phase: Phase 4
• First received: June 2, 2016
• Last updated: April 4, 2017
• Start date: March 2016
• Est. completion date: November 2016

Study information

• Verified date: April 2017
• Source: University of Bern
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, the investigators pose the question which influence the opioid circuit has on positive valent situations in dreams.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

• Written informed consent

• Healthiness

• Good capacity of remembering dreams

• No opiate consumption

Exclusion Criteria:

• Simultaneous participation in other studies

• Addictive disorder

• Abnormal liver function

• Abnormal kidney function

• Hypersensitivity to active ingredient or pharmaceutical additives

• Hereditary galactose intolerance

• Lactase deficiency

• Glucose-galactose malabsorption

• Intake of opioid medication

Related Conditions & MeSH terms

• Neuroscience of Dreaming, Healthy

Intervention

Drug:
• Naltrexone
one week

Other:
• Placebo
one week

Locations

Country	Name	City	State
Switzerland	University of Bern	Bern

Sponsors (2)

Lead Sponsor	Collaborator
University of Bern	University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VAS-difference concerning the emotional valence of dreams	Difference between the mean values of emotional valence of dreams reported in the conditions (Naltrexone, Placebo), as captured in VAS [visual analog scales] for every dream	7 days per condition (Naltrexone, Placebo), intermitted by 14 days of washout
Secondary	Semiquantitative score of emotional valence of dreams	Based on computational linguistic analysis of the dreams	7 days per condition (Baseline, Naltrexone, Placebo), intermitted by 14 days of washout
Secondary	Qualitative score of emotional valence of dreams	Based on lexical coding of the dreams	7 days per condition (Baseline, Naltrexone, Placebo), intermitted by 14 days of washout